Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00am ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00am to 12:00pm ET. Both presentations will be accessible for replay through Oculis' website.
Oculis Holding AG (Nasdaq: OCS), societ脿 biofarmaceutica globale specializzata in patologie oftalmiche e neuro-oftalmiche, ha annunciato la partecipazione al H.C Wainwright 5th Annual Ophthalmology Virtual Conference il 13 agosto 2025.
Sono previste due presentazioni principali: CFO Sylvia Cheung terr脿 un aggiornamento aziendale trasmesso via webcast alle 7:00 ET, mentre R&D President Snehal Shah parteciper脿 a una tavola rotonda sugli asset in fase pivotale per i disturbi retinici dalle 11:00 alle 12:00 ET. Entrambe le presentazioni saranno disponibili in replica sul sito web di Oculis.
Oculis Holding AG (Nasdaq: OCS), compa帽铆a biofarmac茅utica global especializada en afecciones oft谩lmicas y neurooft谩lmicas, anunci贸 su participaci贸n en el H.C Wainwright 5th Annual Ophthalmology Virtual Conference el 13 de agosto de 2025.
Se han programado dos presentaciones principales: CFO Sylvia Cheung ofrecer谩 una actualizaci贸n corporativa v铆a webcast a las 7:00 ET, mientras que R&D President Snehal Shah participar谩 en una mesa redonda sobre activos en fase pivotal para trastornos retinianos de 11:00 a 12:00 ET. Ambas presentaciones estar谩n disponibles en reproducci贸n en el sitio web de Oculis.
Oculis Holding AG (Nasdaq: OCS), 鞎堦臣 氚� 鞁犼步鞎堦臣 歆堩櫂鞚� 鞝勲鞙茧 頃橂姅 旮�搿滊矊 氚旍澊鞓れ牅鞎� 須岇偓臧� H.C Wainwright 5th Annual Ophthalmology Virtual Conference鞐� 2025雲� 8鞗� 13鞚� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
霊� 臧�歆� 欤检殧 氚滍憸臧� 鞓堨爼霅橃柎 鞛堨姷雼堧嫟: CFO Sylvia Cheung電� ET 旮办 鞓れ爠 7鞁滌棎 鞗轨簮鞀ろ姼搿� 旮办梾 鞐呺嵃鞚错姼毳� 歆勴枆頃橁碃, R&D President Snehal Shah電� ET 旮办 鞓れ爠 11鞁滊秬韯� 鞝曥槫旯岇 毵濍 歆堩櫂 甏�霠� 頂茧炒韮� 雼硠(欷戩殧 雼硠) 鞛愳偘鞚� 欤检牅搿� 頃� 韺剱 韱犽鞐� 彀胳棳頃╇媹雼�. 霊� 氚滍憸 氇憪 Oculis 鞗轨偓鞚错姼鞐愳劀 雼れ嫓氤搓赴搿� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Oculis Holding AG (Nasdaq: OCS), soci茅t茅 biopharmaceutique mondiale sp茅cialis茅e dans les affections ophtalmiques et neuro-ophtalmiques, a annonc茅 sa participation au H.C Wainwright 5th Annual Ophthalmology Virtual Conference le 13 ao没t 2025.
Deux pr茅sentations principales sont pr茅vues听: CFO Sylvia Cheung pr茅sentera une mise 脿 jour d'entreprise diffus茅e en webcast 脿 7h00 ET, tandis que R&D President Snehal Shah participera 脿 un panel sur les actifs en phase pivotale pour les affections r茅tiniennes de 11h00 脿 12h00 ET. Les deux pr茅sentations seront accessibles en replay sur le site d'Oculis.
Oculis Holding AG (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen, das sich auf ophthalmologische und neuro-ophthalmologische Erkrankungen spezialisiert hat, gab seine Teilnahme am H.C Wainwright 5th Annual Ophthalmology Virtual Conference am 13. August 2025 bekannt.
Es sind zwei Hauptpr盲sentationen vorgesehen: CFO Sylvia Cheung wird um 7:00 Uhr ET ein Unternehmens-Update per Webcast vorstellen, w盲hrend R&D President Snehal Shah von 11:00 bis 12:00 Uhr ET an einer Podiumsdiskussion 眉ber Assets in pivotaler Phase f眉r Netzhauterkrankungen teilnimmt. Beide Pr盲sentationen werden zur Wiedergabe auf der Website von Oculis verf眉gbar sein.
- None.
- None.
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (鈥淥culis鈥�), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis鈥� management will be participating in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
- Sylvia Cheung, Oculis鈥� Chief Financial Officer, will be presenting a corporate update which will be made available for replay via webcast at 7:00am ET
- Snehal Shah, Oculis鈥� President of R&D, will be participating in a live panel discussion from 11:00am to 12:00pm ET, on Pivotal-Stage Assets for Retinal Disorders. The panel discussion will also be made available via webcast for replay.
Links to access the corporate update presentation and the panel discussion will be posted to Oculis鈥� website on the听听page under the Investors & Media section.
- ENDS -
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis鈥� highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNF伪 in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit:
Oculis Contacts
Ms. Sylvia Cheung, CFO
听
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
听
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
FAQ
When is Oculis (OCS) presenting at the H.C Wainwright Ophthalmology Conference 2025?
Who are the Oculis executives presenting at the H.C Wainwright Conference?
How can investors access Oculis' (OCS) H.C Wainwright Conference presentations?
What topics will be covered in Oculis' panel discussion at the H.C Wainwright Conference?
